Form 4: Nascent Biotech CEO Sean Carrick Acquires 225,000 Shares of Common Stock

Nascent Biotech's President and CEO, Sean Carrick, acquired 225,000 shares of common stock at a price of $0.1845 per share on March 31, 2024, as part of his employment contract.

Summary

• On March 31, 2024, Sean Carrick, the President and CEO of Nascent Biotech Inc., acquired 225,000 shares of common stock.
• The acquisition was made at a price of $0.1845 per share.
• The shares were granted as part of Carrick's employment contract with the company.
• Following the transaction, Carrick directly owns 22,934,007 shares of Nascent Biotech Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While insider buying can be positive, this acquisition is part of an employment contract, making it a routine transaction rather than a discretionary investment.

Positives

• The CEO's acquisition of shares could be seen as a positive signal, indicating confidence in the company's future prospects.

Management Comments

• The shares were granted as part of the employment contract with the Company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Key Dates

Keywords

Sean Carrick, Nascent Biotech, NBIO, Common Stock, Acquisition, Form 4, Insider Trading, Employment Contract